Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zanzalintinib - Exelixis

Next Previous
X
Search
Drug Profile

Zanzalintinib - Exelixis

Alternative Names: XL-092

Latest Information Update: 23 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Exelixis
  • Developer Bristol-Myers Squibb; Exelixis
  • Class Amides; Antineoplastics; Cyclopropanes; Fluorobenzenes; Phenyl ethers; Quinolines; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Proto-oncogene protein c-mer inhibitors; Proto-oncogene protein c-met inhibitors; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Colorectal cancer; Renal cell carcinoma
  • Phase II/III Squamous cell cancer
  • Phase II Liver cancer
  • Phase I Solid tumours

Most Recent Events

  • 09 Dec 2024 Phase-II clinical trials in Liver cancer (Inoperable/Unresectable, First-line therapy, Combination therapy) in USA (PO) (NCT06698250)
  • 20 Nov 2024 University of Pittsburgh plans the phase II ZENOBIA trial for Hepatocellular Carcinoma (Inoperable/Unresectable, First-line therapy, Combination therapy) (PO), in December 2024 (NCT06698250)
  • 14 Oct 2024 Exelixis and Merck enters into clinical development collaboration to evaluate zanzalintinib in combination with pembrolizumab and WELIREG in clinical trials for head and neck cancer and renal cell carcinoma

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top